The Latest News
Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award
Valeritas, Inc., a leader in simple, disposable basal-bolus insulin delivery technology designed for patients with Type 2 diabetes, announced today that it has received a 2014 Cardinal Health Supply Chain Excellence Award. The award was presented October 16th at Cardinal's annual Business Partners Conference in Columbus, Ohio.
The Cardinal Health Supply Chain Excellence Award recipients are judged across a variety of metrics specifically targeted at the importance of developing collaborative relationships with manufacturers and providing exceptional service to each and every one of Cardinal's valued business partners. These metrics recognize actions taken by its business partners to enhance service levels and create efficiencies in the supply chain, including execution on new product launches. Of the over 800 companies eligible for the 2014 award, only 104 received the award.
"We are honored to receive this award and would like to thank Cardinal for recognizing Valeritas. Receiving this award is a result of our commitment to working with our wholesaler partners to support our goal of making V-Go® readily available to patients, especially at retail pharmacies," said Kristine Peterson, Chief Executive Officer of Valeritas. "Providing exceptional service throughout the distribution channel will be important as we continue to execute our strategy of increasing our U.S. commercial reach and bringing this simple, effective and discreet treatment option to the larger population of patients with Type 2 diabetes requiring insulin."
About the V-Go® Disposable Insulin Delivery Device
V-Go® is a small, discreet and easy-to-use disposable insulin delivery device for the delivery of basal-bolus insulin therapy in adults with Type 2 diabetes. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery by releasing a single type of insulin at a continuous preset basal rate over a 24–hour period and also providing for on-demand bolus dosing around mealtimes, without the need for electronics or programming.
V-Go® is mechanical and operates for 24 hours without electronics, batteries, infusion sets or programming. It is worn on the skin under clothing and measures just 2.4 inches wide by 1.3 inches long by 0.5 inches thick, weighing approximately one ounce when filled with insulin.
Important Risk Information: If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Disposable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with the V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.
About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes. Valeritas' portfolio is headlined by the V-Go® disposable insulin delivery device, which is primarily distributed through retail pharmacies.
V-Go® meets an adult Type 2 diabetes patient's insulin needs by providing a treatment that is simple, convenient and easy-to-use. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery by releasing a single type of insulin at a continuous preset basal rate over a 24-hour period and on-demand bolus dosing around mealtime.
Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in a state-of-the-art facility in Shrewsbury, Massachusetts. For more information, visit www.valeritas.com